Intelligence · Clinical Pipeline
Anaxis Pharma Pipeline
All ClinicalTrials.gov programs at Anaxis Pharma — phase, modality, and trial IDs.
- Programs
- 204
Quick answer
Anaxis Pharma has 204 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
-
Tecartus 0.4 - 2 x 10e8 cells dispersion for infusion
Lacuna Pharma Pty Ltd
Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) Relapsed/Refractory B-cell non-Hodgkin lymphoma (r/r NHL)
1 trial -
The clinical trial to study a new drug, AP-2.
Lacuna Pharma Pty Ltd
ALS and related disorders like frontotemporal dementia and Alexander disease.
1 trial -
The goal of this clinical study is to learn more about the safety and dosing of the study drugs, KITE-363 and KITE-753, in participants with relapsed and/or refractory B-cell lymphoma.
Lacuna Pharma Pty Ltd
Relapsed and/or Refractory B-cell Lymphoma
1 trial -
The pivotal bioequivalence study comparing the test product to the reference product, which belong to the group of medicines used in the treatment of type 2 diabetes mellitus when the condition cannot be adequately controlled by diet and exercise alone.
Lacuna Pharma Pty Ltd
Not applicable (submitted trial is a BE study in healthy subjects).
1 trial -
The pivotal bioequivalence study comparing the test product to the reference product, which belongs to the group of medicines used in treatment and prevention of Influenza.
Lacuna Pharma Pty Ltd
influenza
1 trial -
The pivotal bioequivalence study comparing the test product to the reference product, which belongs to the group of medicines used in treatment of schizophrenia in adult patients.
Lacuna Pharma Pty Ltd
Not applicable (submitted trial is a BE study in healthy subjects).
1 trial -
The pivotal bioequivalence study comparing the test product to the reference product, which belongs to the group of medicines used in treatment of schizophrenia in adults patients.
Lacuna Pharma Pty Ltd
Bioequivalence study under fasting conditions
1 trial -
The pivotal bioequivalence study comparing the test product to the reference product, which belongs to the group of medicines used in treatment of type 2 diabetes mellitus in adults and children aged 10 years and above, and heart failure and chronic kidney disease in adults patiens.
Lacuna Pharma Pty Ltd
Not applicable (submitted trial is a BE study in healthy subjects.
1 trial -
This is a clinical trial (study), to be conducted at multiple clinical sites, of an oral study drug (EP262) that will be investigated in adult participants with Chronic Inducible Urticaria (CIndU) to assess if it is safe and improves reactions to known CIndU triggers.
Lacuna Pharma Pty Ltd
Chronic Inducible Urticaria
1 trial -
Treatment of Respiratory Complications Associated with COVID-19, Influenza A, Metapneumovirus, Respiratory Syncytial Virus (RSV) Infection Using Wharton’s Jelly (WJ)-Umbilical Cord (UC) Mesenchymal Stromal Cells (ProTrans®): open Phase IB Clinical Trial
Lacuna Pharma Pty Ltd
Respiratory viral disease, COVID-19, Influenza A, Metapneumovirus, Respiratory syncytial virus Infection
1 trial -
Trial of the novel peroral anti-tumor treatment in patients with solid tumors
Lacuna Pharma Pty Ltd
Metastatic or locally advanced solid tumors for which no standard therapy exists or standard therapy has failed: tumors of lung, head and neck, colon, stomach, esophagus, breast, ovary and/or fallopian tube or primary peritoneal high-grade serous carcinoma
1 trial -
Trial to evaluate the administration of IDOR-1134-2831 vaccine in healthy participants
Lacuna Pharma Pty Ltd
Clostridioides difficile (C. difficile)
1 trial
Frequently asked questions
How many pipeline programs does Anaxis Pharma have?
204 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.
Data attribution: Data sources · All pipeline programs